CDEK
← All drugs Report issue

palmitoylethanolamide

Small moleculeexperimental

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator. — Wikipedia

Clinical trial activity

42 trials · 55 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
18
Phase 3
4
Phase 4
8

Earliest trial started Apr 1, 2009 (NCT00718315)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCCCCCCCCCCCC(=O)NCCO
Mol. weight
299.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • endocannabinoid palmitoylethanolamide
  • impulsin
  • mimyx
  • n-(2-hydroxyethyl)palmitamide
  • n-(2-hydroxyethyl)palmitate
  • n-palmitoylethanolamine
  • palmidrol
  • palmidrol
  • palmidrol
  • palmidrol
  • palmidrol
  • palmidrol
  • palmitic acid monoethanolamide
  • palmitic monoethanolamide
  • palmitoylethanolamide
  • palmitoylethanolamide
  • palmitoylethanolamide
  • palmitoylethanolamide
  • palmitoyl ethanol amide
  • palmitylethanolamide
  • palmotoyletahnolamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07028528Phase 2Jul 1, 2025Gencor, RDC Clinical Pty Ltd
NCT06777680N/AJan 31, 2025Ospedali Riuniti Trieste
NCT06717867Phase 2Jan 31, 2025Gencor, RDC Clinical Pty Ltd
NCT06718452N/AJan 2, 2025University of Campania Luigi Vanvitelli
NCT06694337N/ADec 1, 2024Liaquat University of Medical & Health Sciences
NCT06741358Phase 4Oct 11, 2024I.R.C.C.S. Fondazione Santa Lucia
NCT06351917Phase 4Apr 24, 2024RDC Clinical Pty Ltd
NCT05766969Phase 1/Phase 2 (Phase 2)Jun 5, 2023Pure Green Pharmaceuticals
NCT05810116Phase 4May 19, 2023RDC Clinical Pty Ltd
NCT06229977Phase 2May 17, 2023Baszucki Brain Research Fund, University of Texas at Houston
NCT05652907Phase 2Dec 31, 2022FSD Pharma
NCT06063369Phase 2Dec 21, 2022The Israeli Medical Center for Alzheimer's
NCT07013890Phase 4Nov 2, 2022University of Turin
NCT05406726N/AOct 31, 2022University of Maryland
NCT05480072Early Phase 1 (Phase 1)Aug 31, 2022Harvard University
NCT05246670Phase 2May 16, 2022Academic and Community Cancer Research United, National Cancer Institute (NCI)
NCT05317676Phase 2Apr 30, 2022Gencor, University of California, Irvine
NCT05126888Phase 2Feb 28, 2022Gottfried Wilhelm Leibniz Universität Hannover, SciSparc
NCT05239390Phase 2Dec 29, 2021The Israeli Medical Center for Alzheimer's
NCT05877781N/ANov 29, 2021Katholieke Universiteit Leuven
Showing 20 of 42 trials
Page 1 / 3

Organizations

Research & Development (55)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RDC Clinical Pty LtdFor profit6632021
GencorFor profit3012022
I.R.C.C.S. Fondazione Santa LuciaAcademic/Hospital3222019
Therapix Biosciences Ltd.For profit3222017
Epitech Group SpAFor profit2212020
FSD PharmaFor profit2212020
The Israeli Medical Center for Alzheimer'sAcademic/Hospital2212021
Academic and Community Cancer Research UnitedAcademic/Hospital1112022
Arizona State UniversityAcademic/Hospital1112020
Azienda Ospedaliera San Giovanni AddolorataAcademic/Hospital1012020
Azienda Ospedaliera Sant'Andrea, RomaAcademic/Hospital1012020
Azienda Ospedaliera Universitaria Sant'Andrea di RomaAcademic/Hospital1012020
Baszucki Brain Research FundAcademic/Hospital1012023
CM&D PharmaFor profit1112010
Dicentra Inc.For profit1012021
FGK Clinical Research GmbHFor profit1012018
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1012022
Hannover Medical SchoolAcademic/Hospital1012018
Harvard UniversityAcademic/Hospital1112022
Hospital of Vipiteno-SterzingAcademic/Hospital1112021
55 organizations
Page 1 / 3